Evaluation of the possible effect of Ursodeoxycholic Acid to treat rheumatoid arthritis induced in the Rat model in comparison with Diclofenac.

Authors

  • Yamama Raad Department of Pharmacology and Toxicology College of Pharmacy, University of Baghdad, Baghdad, Iraq
  • Ahmed Hamed Jwaid Department of Pharmacology and Toxicology College of Pharmacy, University of Baghdad, Baghdad, Iraq

DOI:

https://doi.org/10.31351/vol33iss2pp147-155

Keywords:

rheumatoid arthritis (RA), ursodeoxycholic acid (UDCA), Complete Freund adjuvant (CFA)

Abstract

Background: It is well known that ursodeoxycholic acid (UDCA) has notable impacts on the liver, However, tiny amount of knowledge available on how it affects autoimmune illness. This research was done to see an advantage that might exist of using UDCA in Rheumatoid arthritis (RA).

Methods: In order to accomplish this objective, adult either sex rats were divided  into 4 groups: Normal control (sodium bicarbonate 5% p.o. for 21 days),CFA (0.1 ml CFA footpad intradermal injection),FCA+ Diclofenac (5 mg/kg p.o for 21 days),FCA+ UDCA (100 mg/kg p.o. for 21 days).

Results: UDCA (100 mg/kg p.o.) show significantly a rise in Body Mass also significantly  reduce in Arthritic Oedema score in comparison with induction group . RBC, WBC, and ESR were Hematological UDCA therapy of animals Evaluation findings  RBC increased noticeably and WBC ,ESR levels drop noticeably. a considerable drop in TNFα and RF biochemical parameters evaluated in UDCA treatment group.

Keywords: rheumatoid arthritis (RA); ursodeoxycholic acid (UDCA) and Complete Freund adjuvant (CFA)

References

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806.

Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009; 373 (9664) :659 –72.

Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–96.

Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014.

5. Majeed IA, Al-Shawi NN. Effects of omega-3 co-administered with therapeutic dose of lornoxicam on male rats’ liver. Iraqi J Pharm Sci. 2019;28(2):159–64.

Nafeer SA, Zalzala MH. Possible amelioration of the severity of nutritional steatohepatitis by guggulsterone in mice. Iraqi J Pharm Sci. 2019;28(1):17–23.

Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol. 2004;36(3):372–8.

Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338–48.

Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–47.

Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther. 2012;91(1):30–43.

Horton SC, Nam JL, Buch MH. Safety of biologics in rheumatoid arthritis. Int J Clin Rheumtol. 2012;7(4):425–51.

Hofmann AF, Roda A. Physicochemical properties of bile acids and their relationship to biological properties: An overview of the problem. J Lipid Res. 1984;25(13):1477–89.

Hofmann AF, Mysels KJ. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J Lipid Res. 1992;33(5):617–26.

Willart MAM, Van Nimwegen M, Grefhorst A, Hammad H, Moons L, Hoogsteden HC, et al. Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. Allergy Eur J Allergy Clin Immunol. 2012;67(12):1501–10.

O’Dwyer AM, Lajczak NK, Keyes JA, Ward JB, Greene CM, Keely SJ. Ursodeoxycholic acid inhibits TNFα-induced IL-8 release from monocytes. Am J Physiol - Gastrointest Liver Physiol. 2016;311(2):G334–41.

Okan A, Astarcioglu H, Tankurt E, Sagol O, Altekin E, Astarcioglu I, et al. Effect of Ursodeoxycholic Acid on Hepatic Steatosis in Rats. Dig Dis Sci. 2002;47(11):2389–97.

Weng W, Wang F, He X, Zhou K, Wu X, Wu X. Protective effect of Corynoline on the CFA induced Rheumatoid arthritis via attenuation of oxidative and inflammatory mediators. Mol Cell Biochem. 2021;476(2):831–9.

Sharma M, Chaudhary D. Exploration of bromelain laden nanostructured lipid carriers: An oral platform for bromelain delivery in rheumatoid arthritis management. Int J Pharm. 2021;594:120176.

Olausson M, Mjörnstedt L, Wramner L, Persson H, Karlberg I, Friman S. Adjuvant treatment with ursodeoxycholic acid prevents acute rejection in rats receiving heart allografts BT - Transplant International Official Journal of the European Society for Organ Transplantation. In: Kootstra G, Opelz G, Buurman WA, van Hooff JP, MacMaster P, Wallwork J, editors. Berlin, Heidelberg: Springer Berlin Heidelberg; 1992. p. 539–41.

Zhang R-X, Fan AY, Zhou A-N, Moudgil KD, Ma Z-Z, Lee DY-W, et al. Extract of the Chinese herbal formula Huo Luo Xiao Ling Dan inhibited adjuvant arthritis in rats. J Ethnopharmacol. 2009;121(3):366–71.

Hunneyball IM, Crossley MJ, Spowage M. Pharmacological studies of antigen-induced arthritis in BALB/c mice I. Characterization of the arthritis and the effects of steroidal and non-steroidal anti-inflammatory agents. Agents Actions. 1986;18(3):384–93.

Martín AI, Castillero E, Granado M, López-Menduiña M, Villanúa MA, López-Calderón A. Adipose tissue loss in adjuvant arthritis is associated with a decrease in lipogenesis, but not with an increase in lipolysis. J Endocrinol. 2008;197(1):111–9.

Tatsumura T, Sato H, Yamamoto K, Ueyama T. Ursodeoxycholic acid prevents gastrointestinal disorders caused by anticancer drugs. Jpn J Surg. 1981;11(2):84–9.

Duer-Jensen A, Hørslev-Petersen K, Hetland ML, Bak L, Ejbjerg BJ, Hansen MS, et al. Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. Arthritis Rheum. 2011 Aug;63(8):2192–202.

McGonagle D, Conaghan PG, O’Connor P, Gibbon W, Green M, Wakefield R, et al. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: A controlled magnetic resonance imaging study. Arthritis Rheum. 1999 Aug;42(8):1706–11.

McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–42.

Westwood OMR, Nelson PN, Hay FC. Rheumatoid factors: what’s new? Rheumatology. 2006 Apr;45(4):379–85.

Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM An Int J Med. 2010 Mar;103(3):139–46.

Ramsay ES, Lerman MA. How to use the erythrocyte sedimentation rate in paediatrics. Arch Dis Child Educ Pract Ed. 2015;100(1):30–6.

Downloads

Published

2024-06-29